Indexed on: 28 Sep '20Published on: 27 Sep '20Published in: Hematological Oncology
The prognosis of diffuse large B-cell lymphoma (DLBCL) having MYC rearrangement (MYC-R), including double hit lymphoma (DHL), is poor by standard immunochemotherapy. To evaluate the significance of hematopoietic stem cell transplantation (SCT) for DLBCL with MYC-R, we retrospectively analyzed Japanese SCT registry data. In total, 54 patients with DLBCL with MYC-R were identified from 4,336 registered adult DLBCL patients. Detailed clinical and cytogenetic information were obtained for 48 patients. The median age at diagnosis of the 48 patients was 54.5 (range 21-67) years. Twenty-six (54%) patients had MYC-R only (single hit), and 22 (46%) had MYC-R and BCL2, and/or BCL6 rearrangement (double/triple hit). In 12 patients who received auto-SCT during the first complete response (CR), both the 2-year overall survival (OS) and progression-free survival (PFS) rates were 75.0% (95% confidence interval [CI], 40.8% to 91.2%). In 20 patients who received auto-SCT after relapsed or refractory state, the 2-year OS and PFS rates were 68.2% (95% CI, 41.9% to 84.5%) and 59.6% (95% CI, 35.1% to 77.4%), respectively. In 17 patients who received allo-SCT, only 4 patients underwent SCT in CR. The 2-year OS and PFS rates were 29.4% (95% CI, 10.7% to 51.1%) and 17.6% (95% CI, 4.3% to 38.3%), respectively. The rate of non-relapse mortality at 1 year was 41.2% (95% CI, 17.1% to 64.0%) in this group. The outcomes of single hit and double or triple hit were not different. These findings suggest that auto-SCT may be effective for MYC-R DLBCL, including DHL patients of chemosensitive relapsed or refractory state. Since most patients received allo-SCT not in CR, the outcome of allo-SCT was unsatisfactory due to high NRM and early relapse. To clarify the role of allo-SCT for MYC-R DLBCL, further accumulation of patients is necessary. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.